Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis

Breast Cancer Research and Treatment

Volumn 122, Issue 3, 2010, Pages 843-851

  Van Herk Sukel, Myrthe P P ^a   Van De Poll Franse, Lonneke V ^b,c   Voogd, Adri C ^b,d   Nieuwenhuijzen, Grard A P ^e   Coebergh, Jan Willem W ^b,f   Herings, Ron M C ^a,f  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant endocrine therapy; Aromatase inhibitors; Discontinuation; Early stage breast cancer; Recurrence; Switching; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; EXEMESTANE; FULVESTRANT; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; BREAST NEOPLASMS; DRUG EFFECTS; ENDOCRINE SYSTEM; EPIDEMIOLOGY; FOLLOW UP; MIDDLE AGED; NETHERLANDS; PATHOLOGY; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENDOCRINE SYSTEM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NETHERLANDS; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 77955559438     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0724-3     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 9472 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
2. EP Winer C Hudis HJ Burstein AC Wolff KI Pritchard JN Ingle RT Chlebowski R Gelber SB Edge J Gralow, et al. 2005 American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004 J Clin Oncol 23 3 619 629 10.1200/JCO.2005.09.121 1:CAS:528:DC%2BD2MXitVartb4%3D 15545664 (Pubitemid 46224240)
3. DM Waterhouse KA Calzone C Mele DE Brenner 1993 Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring J Clin Oncol 11 6 1189 1197 1:STN:280:DyaK3s3nsVentQ%3D%3D 8501505
4. TI Barron R Connolly K Bennett J Feely MJ Kennedy 2007 Early discontinuation of tamoxifen: a lesson for oncologists Cancer 109 832 839 10.1002/cncr.22485 1:CAS:528:DC%2BD2sXjsVKns7s%3D 17243168 (Pubitemid 46333524)
5. C McCowan J Shearer PT Donnan JA Dewar M Crilly AM Thompson TP Fahey 2008 Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer Br J Cancer 99 11 1763 1768 10.1038/sj.bjc.6604758 1:CAS:528:DC%2BD1cXhsVajtbrL 18985046
6. C Owusu DS Buist TS Field TL Lash SS Thwin AM Geiger VP Quinn F Frost M Prout MU Yood, et al. 2008 Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer J Clin Oncol 26 4 549 555 10.1200/JCO.2006.10.1022 18071188 (Pubitemid 351264347)
7. G Kimmick R Anderson F Camacho M Bhosle W Hwang R Balkrishnan 2009 Adjuvant hormonal therapy use among insured, low-income women with breast cancer J Clin Oncol 27 21 3445 3451 10.1200/JCO.2008.19.2419 19451445
8. LS Schwartzberg P Cobb F Senecal D Henry K Kulig MS Walker AC Houts EJ Stepanski 2009 Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer Breast 18 2 78 83 10.1016/j.breast.2009.01.002 19342237
9. MP van Herk-Sukel LV van de Poll-Franse VE Lemmens G Vreugdenhil JF Pruijt JW Coebergh RM Herings 2010 New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO Record Linkage System Eur J Cancer 46(2) 395 404 10.1016/j.ejca.2009.09.010
10. EJ Rutgers JW Nortier MK Tuut G van Tienhoven H Struikmans M Bontenbal MF von Meyenfeldt G Vreugdenhil T Benraadt B Garssen, et al. 2002 Dutch Institute for Healthcare Improvement guideline, 'Treatment of breast cancer' Ned Tijdschr Geneeskd 146 45 2144 2151 12474555
11. Kwaliteitsinstituut voor de Gezondheidszorg CBO (2004) Guideline 'Treatment of breast cancer'. Utrecht, the Netherlands
12. SE Andrade KH Kahler F Frech KA Chan 2006 Methods for evaluation of medication adherence and persistence using automated databases Pharmacoepidemiol Drug Saf 15 8 565 574 10.1002/pds.1230 16514590 (discussion 575-567) (Pubitemid 44336271)
13. JA Cramer A Roy A Burrell CJ Fairchild MJ Fuldeore DA Ollendorf PK Wong 2008 Medication compliance and persistence: terminology and definitions Value Health 11 1 44 47 18237359
14. V Catalan J Lelorier 2000 Predictors of long-term persistence on statins in a subsidized clinical population Value Health 3 6 417 426 10.1046/j.1524-4733.2000.36006.x 1:STN:280:DC%2BD28%2FnvFCmuw%3D%3D 16464201 (Pubitemid 32066649)
15. L Atkins L Fallowfield 2006 Intentional and non-intentional non-adherence to medication amongst breast cancer patients Eur J Cancer 42 14 2271 2276 10.1016/j.ejca.2006.03.004 16644208 (Pubitemid 44307611)
16. KL Kahn EC Schneider JL Malin JL Adams AM Epstein 2007 Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use Med Care 45 5 431 439 10.1097/01.mlr.0000257193.10760.7f 17446829
17. AH Partridge PS Wang EP Winer J Avorn 2003 Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer J Clin Oncol 21 4 602 606 10.1200/JCO.2003.07.071 1:CAS:528:DC%2BD2cXpsVGrtbs%3D 12586795 (Pubitemid 46621892)
18. ME Charlson P Pompei KL Ales CR MacKenzie 1987 A new method of classifying prognostic comorbidity in longitudinal studies: development and validation J Chronic Dis 40 5 373 383 10.1016/0021-9681(87)90171-8 1:STN:280:DyaL2s7ms1GnsQ%3D%3D 3558716 (Pubitemid 17055592)
19. van de Velde CJ, Verma S, van Nes JG, Masterman C, Pritchard KI (2009) Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treat Rev. doi:10.1016/j.ctrv.2009.10.003
20. S Verma S Sehdev A Joy Y Madarnas J Younus JA Roy 2009 An updated review on the efficacy of adjuvant endocrine therapies in hormone receptor-positive early breast cancer Curr Oncol 16 Supplement 2 S1 S13 1:STN:280: DC%2BD1MrkvFOiuw%3D%3D 19672416
21. EA Grunfeld MS Hunter P Sikka S Mittal 2005 Adherence beliefs among breast cancer patients taking tamoxifen Patient Educ Couns 59 1 97 102 10.1016/j.pec.2004.10.005 16198223 (Pubitemid 41399883)
22. V Murthy G Bharia R Sarin 2002 Tamoxifen non-compliance: does it matter? Lancet Oncol 3 11 654 10.1016/S1470-2045(02)00895-1 12424066 (Pubitemid 35314907)
23. S Demissie RA Silliman TL Lash 2001 Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women J Clin Oncol 19 2 322 328 1:CAS:528:DC%2BD3MXhtVektrk%3D 11208822
24. AK Fink J Gurwitz W Rakowski E Guadagnoli RA Silliman 2004 Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer J Clin Oncol 22 16 3309 3315 10.1200/JCO.2004.11.064 15310774 (Pubitemid 41103687)
25. TL Lash MP Fox JL Westrup AK Fink RA Silliman 2006 Adherence to tamoxifen over the five-year course Breast Cancer Res Treat 99 2 215 220 10.1007/s10549-006-9193-0 16541307 (Pubitemid 44268270)
26. AH Partridge A LaFountain E Mayer BS Taylor E Winer A Asnis-Alibozek 2008 Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer J Clin Oncol 26 4 556 562 10.1200/JCO.2007.11.5451 1:CAS:528:DC%2BD1cXis1alsrc%3D 18180462 (Pubitemid 351264348)
27. V Ziller M Kalder US Albert W Holzhauer M Ziller U Wagner P Hadji 2009 Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer Ann Oncol 20 3 431 436 10.1093/annonc/mdn646 1:STN:280: DC%2BD1M7mvVynsA%3D%3D 19150950
28. van Nes JG, Seynaeve C, Maartense E, Roumen RM, de Jong RS, Beex LV, Meershoek-Klein Kranenbarg WM, Putter H, Nortier JW, van de Velde CJ (2009) Patterns of care in Dutch postmenopausal patients with hormone-sensitive early breast cancer participating in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Ann Oncol. doi:10.1093/annonc/mdp419